Trial Profile
An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Therapeutic Use
- Acronyms RELAX
- Sponsors Lexicon Pharmaceuticals; TerSera Therapeutics
- 18 Jan 2022 Status changed from active, no longer recruiting to completed.
- 09 Nov 2021 Results published in the TerSera Therapeutics Media Release
- 09 Nov 2021 According to a TerSera Therapeutics media release, The data were presented in virtual poster sessions during the North American Neuroendocrine Tumor Society's (NANETS) Multidisciplinary NET Medical Symposium on November 3-6, 2021.1